{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:02:21Z","timestamp":1768809741553,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172991"],"award-info":[{"award-number":["82172991"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502089"],"award-info":[{"award-number":["81502089"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773109"],"award-info":[{"award-number":["81773109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20151024"],"award-info":[{"award-number":["BK20151024"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20151582"],"award-info":[{"award-number":["BK20151582"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Research Program for Higher Education in Jiangsu Province","award":["21KJB320015"],"award-info":[{"award-number":["21KJB320015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00428-022-03339-y","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T02:02:39Z","timestamp":1653703359000},"page":"405-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer"],"prefix":"10.1007","volume":"481","author":[{"given":"Ying","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-9365","authenticated-orcid":false,"given":"Zhi-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"7153","key":"3339_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561\u2013566","journal-title":"Nature"},{"issue":"18","key":"3339_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693\u20131703","journal-title":"N Engl J Med"},{"issue":"12","key":"3339_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1097\/JTO.0000000000000361","volume":"9","author":"J Vidal","year":"2014","unstructured":"Vidal J et al (2014) Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. J Thorac Oncol 9(12):1816\u20131820","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3339_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtho.2016.08.145","volume":"12","author":"W Li","year":"2017","unstructured":"Li W et al (2017) Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol 12(1):94\u2013101","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3339_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00432-019-03116-6","volume":"146","author":"P Tian","year":"2020","unstructured":"Tian P et al (2020) Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol 146(4):935\u2013944","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"3339_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/cancers9090118","volume":"9","author":"SR Sabir","year":"2017","unstructured":"Sabir SR et al (2017) EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers (Basel) 9(9):118","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3339_CR7","volume":"1","author":"SI Ou","year":"2020","unstructured":"Ou SI, Zhu VW, Nagasaka M (2020) Catalog of 5\u2019 fusion partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep 1(1):100015","journal-title":"JTO Clin Res Rep"},{"issue":"25","key":"3339_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385\u20132394","journal-title":"N Engl J Med"},{"issue":"7","key":"3339_CR9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","volume":"14","author":"DR Camidge","year":"2019","unstructured":"Camidge DR et al (2019) Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 14(7):1233\u20131243","journal-title":"J Thorac Oncol"},{"key":"3339_CR10","first-page":"147","volume":"11","author":"H Uruga","year":"2018","unstructured":"Uruga H, Mino-Kenudson M (2018) ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharmgenomics Pers Med 11:147\u2013155","journal-title":"Pharmgenomics Pers Med"},{"issue":"6","key":"3339_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1586\/14737159.2016.1172963","volume":"16","author":"E Conde","year":"2016","unstructured":"Conde E et al (2016) Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn 16(6):707\u2013713","journal-title":"Expert Rev Mol Diagn"},{"issue":"20","key":"3339_CR12","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-08-1018","volume":"14","author":"K Takeuchi","year":"2008","unstructured":"Takeuchi K et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14(20):6618\u20136624","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3339_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070839","volume":"8","author":"YC Wu","year":"2013","unstructured":"Wu YC et al (2013) Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE 8(8):e70839","journal-title":"PLoS ONE"},{"issue":"2","key":"3339_CR14","first-page":"70","volume":"3","author":"C Teixido","year":"2014","unstructured":"Teixido C et al (2014) Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res 3(2):70\u201374","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"3339_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","volume":"13","author":"I Letovanec","year":"2018","unstructured":"Letovanec I et al (2018) Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol 13(3):413\u2013425","journal-title":"J Thorac Oncol"},{"issue":"50","key":"3339_CR16","doi-asserted-by":"publisher","first-page":"82943","DOI":"10.18632\/oncotarget.12705","volume":"7","author":"S Dacic","year":"2016","unstructured":"Dacic S et al (2016) ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget 7(50):82943\u201382952","journal-title":"Oncotarget"},{"key":"3339_CR17","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.2147\/OTT.S265974","volume":"13","author":"L Zeng","year":"2020","unstructured":"Zeng L et al (2020) Comparison of next-generation sequencing and ventana immunohistochemistry in detecting ALK rearrangements and predicting the efficacy of first-line crizotinib in patients with advanced non-small cell lung cancer. Onco Targets Ther 13:7101\u20137109","journal-title":"Onco Targets Ther"},{"issue":"5","key":"3339_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/JTO.0000000000000115","volume":"9","author":"MW Wynes","year":"2014","unstructured":"Wynes MW et al (2014) An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9(5):631\u2013638","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3339_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/annonc\/mdu484","volume":"26","author":"MI Ilie","year":"2015","unstructured":"Ilie MI et al (2015) Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK \u2018borderline\u2019-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 26(1):238\u2013244","journal-title":"Ann Oncol"},{"issue":"3","key":"3339_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","volume":"20","author":"M Pekar-Zlotin","year":"2015","unstructured":"Pekar-Zlotin M et al (2015) Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20(3):316\u2013322","journal-title":"Oncologist"},{"issue":"5","key":"3339_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/modpathol.2017.181","volume":"31","author":"JN Rosenbaum","year":"2018","unstructured":"Rosenbaum JN et al (2018) Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol 31(5):791\u2013808","journal-title":"Mod Pathol"},{"key":"3339_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.741142","volume":"11","author":"Z Tao","year":"2021","unstructured":"Tao Z et al (2021) Profiling receptor tyrosine kinase fusions in Chinese breast cancers. Front Oncol 11:741142","journal-title":"Front Oncol"},{"key":"3339_CR23","doi-asserted-by":"crossref","unstructured":"Xiang C et al. (2022)\u00a0Identification and validation of noncanonical RET fusions in non-small-cell lung cancer through DNA and RNA sequencing. J Mol Diagn","DOI":"10.1016\/j.jmoldx.2021.12.004"},{"issue":"1","key":"3339_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15\u201321","journal-title":"Bioinformatics"},{"issue":"1","key":"3339_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas BJ et al (2019) Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol 20(1):213","journal-title":"Genome Biol"},{"issue":"18","key":"3339_CR26","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1002\/cncr.27411","volume":"118","author":"DR Camidge","year":"2012","unstructured":"Camidge DR et al (2012) Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 118(18):4486\u20134494","journal-title":"Cancer"},{"issue":"22","key":"3339_CR27","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","volume":"16","author":"DR Camidge","year":"2010","unstructured":"Camidge DR et al (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16(22):5581\u20135590","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3339_CR28","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","volume":"46","author":"T Sasaki","year":"2010","unstructured":"Sasaki T et al (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46(10):1773\u20131780","journal-title":"Eur J Cancer"},{"issue":"5","key":"3339_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.tranon.2019.02.015","volume":"12","author":"A Guyard","year":"2019","unstructured":"Guyard A et al (2019) Isolated 5\u2019 signals are an atypical pattern to be considered as positive for ALK rearrangement: a brief report of three cases and review of the literature. Transl Oncol 12(5):784\u2013787","journal-title":"Transl Oncol"},{"issue":"3","key":"3339_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2013.01.004","volume":"15","author":"EC Minca","year":"2013","unstructured":"Minca EC et al (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 15(3):341\u2013346","journal-title":"J Mol Diagn"},{"issue":"11","key":"3339_CR31","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.21037\/tlcr-21-570","volume":"10","author":"M Zacharias","year":"2021","unstructured":"Zacharias M et al (2021) Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience. Transl Lung Cancer Res 10(11):4221\u20134234","journal-title":"Transl Lung Cancer Res"},{"issue":"15","key":"3339_CR32","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","volume":"25","author":"R Benayed","year":"2019","unstructured":"Benayed R et al (2019) High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res 25(15):4712\u20134722","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3339_CR33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jtho.2020.01.019","volume":"15","author":"D Cohen","year":"2020","unstructured":"Cohen D et al (2020) Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J Thorac Oncol 15(6):1000\u20131014","journal-title":"J Thorac Oncol"},{"issue":"23","key":"3339_CR34","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167\u20132177","journal-title":"N Engl J Med"},{"key":"3339_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.lungcan.2018.01.026","volume":"118","author":"Y Li","year":"2018","unstructured":"Li Y et al (2018) Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer 118:128\u2013133","journal-title":"Lung Cancer"},{"issue":"28","key":"3339_CR36","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","volume":"34","author":"T Yoshida","year":"2016","unstructured":"Yoshida T et al (2016) Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol 34(28):3383\u20133389","journal-title":"J Clin Oncol"},{"issue":"4","key":"3339_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/annonc\/mdw693","volume":"28","author":"CG Woo","year":"2017","unstructured":"Woo CG et al (2017) Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol 28(4):791\u2013797","journal-title":"Ann Oncol"},{"issue":"13","key":"3339_CR38","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","volume":"68","author":"YL Choi","year":"2008","unstructured":"Choi YL et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68(13):4971\u20134976","journal-title":"Cancer Res"},{"issue":"6","key":"3339_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jtho.2020.02.007","volume":"15","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) Detection of nonreciprocal\/reciprocal ALK translocation as poor predictive marker in patients with first-line crizotinib-treated ALK-rearranged NSCLC. J Thorac Oncol 15(6):1027\u20131036","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3339_CR40","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jtho.2020.02.023","volume":"15","author":"W Li","year":"2020","unstructured":"Li W et al (2020) Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol 15(7):1223\u20131231","journal-title":"J Thorac Oncol"},{"key":"3339_CR41","doi-asserted-by":"crossref","unstructured":"Zhang SS et al (2021)\u00a0Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer 158:126\u2013136","DOI":"10.1016\/j.lungcan.2021.06.012"},{"issue":"10","key":"3339_CR42","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","volume":"29","author":"A Kron","year":"2018","unstructured":"Kron A et al (2018) Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol 29(10):2068\u20132075","journal-title":"Ann Oncol"},{"issue":"4","key":"3339_CR43","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/cam4.2043","volume":"8","author":"P Song","year":"2019","unstructured":"Song P et al (2019) Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. Cancer Med 8(4):1551\u20131557","journal-title":"Cancer Med"},{"issue":"4","key":"3339_CR44","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang C et al (2019) Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. J Thorac Oncol 14(4):726\u2013731","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3339_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jncc.2021.07.005","volume":"1","author":"W Li","year":"2021","unstructured":"Li W et al (2021) Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. J National Cancer Cent 1(4):123\u2013131","journal-title":"Journal of the National Cancer Center"},{"issue":"11","key":"3339_CR46","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31(11):1491\u20131505","journal-title":"Ann Oncol"},{"issue":"4","key":"3339_CR47","doi-asserted-by":"publisher","first-page":"450","DOI":"10.21037\/tlcr.2018.05.14","volume":"7","author":"F Zhou","year":"2018","unstructured":"Zhou F, Zhou C (2018) Lung cancer in never smokers-the East Asian experience. Transl Lung Cancer Res 7(4):450\u2013463","journal-title":"Transl Lung Cancer Res"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03339-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03339-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03339-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T19:08:26Z","timestamp":1663614506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03339-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03339-y","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"5 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were performed in accordance with the Declaration of Helsinki. This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}